Message #8 From:
Stock News Bot Date: August 23, 2006 03:03:00 AM
MDSM News Research Update on Medistem Laboratories Issued by Beacon Equity Research Following Recent News Developments
DALLAS--(BUSINESS WIRE)--Aug. 23, 2006--A new research note has been issued on Medistem Laboratories, Inc. (OTCBB: MDSM) by Beacon Equity Research Senior Research Analyst, Shailesh Dhuri, CFA.
In the report Mr. Dhuri writes, "Medistem Laboratories is an innovative biotechnology company that creates and licenses adult stem cell therapies to international stem cell banks and clinics. The Company is making significant progress in virtually all aspects of its operations. A key development has been the Costa Rican Health Ministry's licensing of Medistem's affiliate, ICM, to begin conducting operations. Other significant developments highlighted include the recent appointment of new senior management and an expanding portfolio of intellectual property."
"Medistem's focus is solely on adult stem cells, which some believe may represent one of the greatest areas for growth in the field of medicine. Under its strategic business plan, the company intends to increase its intellectual property portfolio through its own research and development efforts, as well as through the work conducted by its affiliates."
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of Medistem Laboratories, Inc. (MDSM). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Research has been directly compensated $18,000 for a one year enrollment in its program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
